Ubs Group Ag Renovo Rx, Inc. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RNXT
# of Institutions
16Shares Held
2.87MCall Options Held
0Put Options Held
0-
Bank Of Montreal Toronto, A6975KShares$1.23 Million0.0% of portfolio
-
Bank Of The West975KShares$1.23 Million0.27% of portfolio
-
Adar1 Capital Management, LLC Austin, TX315KShares$397,1410.05% of portfolio
-
Geode Capital Management, LLC Boston, MA233KShares$293,5000.0% of portfolio
-
Nixon Peabody Trust CO Boston, MA97.2KShares$122,4270.01% of portfolio
About RenovoRx, Inc.
- Ticker RNXT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 9,066,860
- Market Cap $11.4M
- Description
- RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, In...